ICER Report Supports Cost Effectiveness of CGRP Inhibitors

Source: Institute for Clinical and Economic Review (ICER)
A recently released Institute for Clinical and Economic Review (ICER) evidence report assessing the comparative clinical effectiveness and value of three calcitonin gene-related peptide (CGRP) inhibitors for prevention of migraine attacks found that the price of the therapies aligns with the value to patients for whom other preventive treatments have failed.
Read the report…

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on print
Share on email
Pain Medicine Journal
Access to this page is restricted to members only! Not a mamber? Join Now!

Ask Us Anything. Anytime.

📝 Fill in your details and we’ll get back to you in no time.
AAPM

American Academy of Pain Medicine